Corcept Therapeutics Inc
Change company Symbol lookup
Select an option...
CORT Corcept Therapeutics Inc
CVS CVS Health Corp
NVAX Novavax Inc
MRK Merck & Co Inc
HYT BlackRock Corporate High Yield Fund, Inc
FNMA Federal National Mortgage Association
CPKF Chesapeake Financial Shares Inc
AGNC Agnc Investment Corp
BYND Beyond Meat Inc
NDENF Central African Gold Inc

Health Care : Pharmaceuticals | Small Cap Growth
Company profile

Corcept Therapeutics Incorporated is a pharmaceutical company engaged in the discovery, development and commercialization of drugs for the treatment of severe metabolic, psychiatric and oncologic disorders. The Company is developing mifepristone, a compound that modulates the effects of cortisol by acting as a competitive antagonist at the glucocorticoid receptor (GR). As of December 31, 2016, it had discovered three structurally distinct series of selective cortisol modulators, all of which share mifepristone's affinity for GR but, unlike mifepristone, do not bind to the progesterone receptor. It is conducting two clinical trials of its selective cortisol modulator, CORT125134. One trial is investigating CORT125134 as a treatment for patients with Cushing syndrome. The second trial is investigating the combination of CORT125134 and nab-paclitaxel (Celgene Corporation's Abraxane) to treat patients with solid-tumor cancers.

Closing Price
Day's Change
-0.30 (-1.67%)
B/A Size
Day's High
Day's Low

10-day average volume:

UPDATE: Buy the worst? Here are 5 destroyed stocks for this bottom-fishing strategy

11:09 am ET October 17, 2020 (MarketWatch)

Shawn Langlois

Back on the last day of 2012, an article published on Money Morning ( laid out the five best- and five worst-performing stocks in the S&P 500 index of the year, in an attempt to divine some insight into where to invest heading in to 2013.

The biggest winners were PulteGroup (PHM), Sprint , Whirlpool (WHR), Expedia (EXPE) and Bank of America (BAC), while the losers were RadioShack , SuperValu, AMD (AMD), Best Buy (BBY) and Apollo Group.

On Reddit, an investor named Spaghetto offered up a "where are they now" kind of look into which group ( has outperformed since then. It's not even close. The losers win by a wide margin.

He determined that betting $1,000 on the winners would have resulted in a gain of more than 250%, bringing the total investment to $2,500. Certainly not a bad return over the course of eight years.

Investing in the worst performers, however, would have delivered about 900% growth to $9,000. AMD's rocket ride obviously has a lot to do with that, but even after stripping that out the other four stocks still would have returned 240%, according to Spaghetto's data dive.

What's the takeaway?

"You shouldn't necessarily overlook 'bad' stocks. Of course, do your due diligence. And definitely don't invest all your eggs there," he wrote. "But conversely, don't ignore picks just because someone tells you to. It might be worthwhile to keep a few 'bad' eggs in a small basket of your larger portfolio. You never know what will come roaring back in five to ten years."

In that spirit, let's take a look at the winners and losers so far this year.

The top five performers on the S&P 500 year-to-date: Etsy (ETSY) (+243%), Nvidia (NVDA) (+141%), West Pharmaceutical Services (WST) (+96%), PayPal (PYPL) (90%) and Amazon (AMZN) (85%).

The losers: Occidental Petroleum (OXY) (-74%), Carnival Corp. (CCL) (-72%), Norwegian Cruise Line Holdings (NCLH) (-72%), Marathon Oil (MRO) (-68%) and TechnipFMC PLC (FTI.FR) (-67%).

We'll check back in 2028 and see whether the strategy holds up.

-Shawn Langlois; 415-439-6400;

(END) Dow Jones Newswires

October 17, 2020 11:09 ET (15:09 GMT)

Copyright (c) 2020 Dow Jones & Company, Inc.

Earnings Calendar and Events Data provided by |Terms of Use| © 2020 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., , and

Copyright © 2020. All rights reserved.